This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results were reported across multiple therapeutic areas, including radiographic and non-radiographic axial spondyloarthritis, microcystic lymphatic malformations, pulmonary arterial hypertension, and obesity. Here's a closer look at the details. FDA Approvals & Rejections Armata Pharma Secures FDA QIDP Designation for AP-SA02 Armata Pharmaceuticals, ...

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products, including KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3] Upcoming Events - Members of Eton's executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 11, 2026, in Miami, Florida [1] - Interested parties can schedule a meeting by contacting their Leerink Partners institutional sales representative [2]

Core Insights - Eton Pharmaceuticals has out-licensed the commercial rights to Increlex® to Esteve Pharmaceuticals for markets outside the U.S. [1][2] - Esteve is expected to leverage its global infrastructure to successfully commercialize Increlex, allowing Eton to focus on growth opportunities within the U.S. [2][3] - The licensing agreement is for up to ten years, with an option for Esteve to acquire international rights in the future [3] Company Overview - Eton Pharmaceuticals specializes in developing and commercializing treatments for rare diseases, currently offering seven commercial products and six additional candidates in late-stage development [4]